News
The latest healthcare news from press releases by leading companies.
Stryker to Acquire Amplitude Vascular Systems, Adding Lithotripsy Technology to Vascular Portfolio
Stryker has signed a definitive agreement to acquire Amplitude Vascular Systems, a privately held medical technology company developing a next-generation intravascular lithotripsy platform designed to...
Read More →Medtronic Sets June 3 Date for Fourth-Quarter and Full Fiscal Year 2026 Results
Medtronic has announced it will report financial results for its fourth quarter and full fiscal year 2026 on Wednesday, June 3, 2026. The fiscal year...
Read More →EU Approves Dupixent as First Targeted Treatment for Young Children with Chronic Spontaneous Urticaria
The European Commission has approved Dupixent (dupilumab) for treating moderate-to-severe chronic spontaneous urticaria in children aged 2 to 11 years who have not responded adequately...
Read More →Novartis Expands Community Health Programs to 30-Plus Countries by 2030 to Address Heart Disease and Cancer Gaps
Novartis has announced plans to expand its community health initiatives from 11 to over 30 countries by 2030, targeting underserved populations with heart disease and...
Read More →Abbott Survey Reveals Gap Between Americans' Belief in Disease Prevention and Their Health Confidence
A new survey commissioned by Abbott and conducted by Kantar among 4,000 U.S. adults has uncovered a significant disconnect between what Americans believe about chronic...
Read More →Sanofi's Bispecific Antibody Lunsekimig Meets Key Endpoints in Asthma and Nasal Polyp Studies
Sanofi has announced positive Phase 2 results for lunsekimig, a bispecific antibody designed to simultaneously block TSLP and IL-13, in two respiratory studies. The AIRCULES...
Read More →EU Approves Sanofi's Rezurock for Chronic Graft-Versus-Host Disease
The European Commission has granted conditional marketing authorization for Sanofi’s Rezurock (belumosudil), a selective ROCK2 inhibitor, to treat chronic graft-versus-host disease in patients aged 12...
Read More →Abbott Integrates Precision Oncology Tests Into Flatiron's OncoEMR Platform
Abbott and Flatiron Health have announced the integration of Abbott’s Precision Oncology test portfolio into OncoEMR, Flatiron’s cloud-based electronic medical record platform. The integration enables...
Read More →Novartis's Fabhalta Slows Kidney Function Decline by Nearly 50% in IgA Nephropathy Trial
Final two-year results from the Phase III APPLAUSE-IgAN study show that Novartis’s Fabhalta (iptacopan) slowed the decline of kidney function by 49.3% compared to placebo...
Read More →Sanofi's Amlitelimab Shows Positive Phase 3 Results in Atopic Dermatitis at AAD Meeting
Sanofi has reported positive Phase 3 trial results for amlitelimab, a monoclonal antibody targeting OX40-ligand, in treating moderate-to-severe atopic dermatitis. The data were presented in...
Read More →EU Panel Recommends Approval of Sanofi's Sarclisa Subcutaneous Formulation for Multiple Myeloma
The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of a subcutaneous formulation of Sanofi’s Sarclisa (isatuximab) for treating multiple...
Read More →Novartis to Acquire Excellergy for Up to $2 Billion, Adding Next-Generation Anti-IgE Therapy
Novartis has agreed to acquire Excellergy, Inc., a private biotech developing next-generation anti-IgE therapies, for up to $2 billion in upfront and milestone payments. The...
Read More →Medtronic Wins FDA Clearance for AI-Enabled Stealth AXiS Surgical System for Brain and ENT Surgery
Medtronic has received FDA clearance for the Stealth AXiS surgical system for use in cranial and ear, nose, and throat procedures, expanding the platform beyond...
Read More →UnitedHealthcare Launches AI-Powered Health Navigation Tool for Millions of Members
UnitedHealthcare has launched Avery, a generative AI companion designed to simplify healthcare navigation for members through the UnitedHealthcare app and myuhc.com. The tool is currently...
Read More →Abbott Schedules First-Quarter 2026 Earnings Release for April 16
Abbott announced it will release first-quarter 2026 financial results on Thursday, April 16, before the market opens. A live webcast of the earnings conference call...
Read More →Sanofi Publishes Q1 2026 Financial Modeling Document Ahead of April Earnings
Sanofi has made its Q1 2026 aide-memoire available on the company’s Investors webpage. The quarterly document supports financial modeling by covering non-comparable items, foreign currency...
Read More →Medtronic Partners with Merit Medical to Offer New Nerve Ablation System for Chronic Lower-Back Pain
Medtronic has entered a distribution agreement with Merit Medical Systems to offer the FDA-cleared ViaVerte system, described as the first and only basivertebral nerve ablation...
Read More →Japan Approves Dupixent as First Targeted Medicine for Adult Bullous Pemphigoid
Japan’s Ministry of Health, Labour and Welfare has approved Dupixent (dupilumab) for treating adults with moderate-to-severe bullous pemphigoid, marking the seventh indication for the drug...
Read More →Novartis Showcases Immunology Portfolio Data Across 20-Plus Abstracts at AAD 2026
Novartis is presenting clinical findings from more than 20 abstracts at the American Academy of Dermatology Annual Meeting, highlighting advances across its immunology portfolio in...
Read More →Medtronic's OmniaSecure Lead Becomes First Defibrillation Lead Approved by FDA for Conduction System Pacing
The FDA has approved an expanded indication for Medtronic’s OmniaSecure defibrillation lead, making it the first defibrillation lead cleared for placement in the left bundle...
Read More →Abbott Closes Exact Sciences Deal, Enters $60 Billion Cancer Diagnostics Market
Abbott has completed its acquisition of Exact Sciences, positioning the healthcare giant as a significant player in the fast-growing $60 billion U.S. cancer screening and...
Read More →Novartis Pays $2 Billion Upfront for Targeted Breast Cancer Drug Candidate SNV4818
Novartis has agreed to acquire SNV4818, a pan-mutant-selective PI3Ka inhibitor in Phase 1/2 development, from Synnovation Therapeutics for $2 billion upfront plus up to $1...
Read More →Abbott's Acquisition of Exact Sciences Set to Close March 23
Abbott confirmed that its acquisition of Exact Sciences is on track to close on March 23, 2026, with the cancer diagnostics company set to become...
Read More →FDA Grants Breakthrough Therapy Designation to Sanofi's Venglustat for Type 3 Gaucher Disease
The FDA has granted Breakthrough Therapy designation to Sanofi’s venglustat, an investigational oral glucosylceramide synthase inhibitor, for treating neurological manifestations of type 3 Gaucher disease....
Read More →UnitedHealth Group to Release First-Quarter 2026 Results on April 21
UnitedHealth Group will release first-quarter 2026 financial results on Tuesday, April 21, 2026, before market opens. The company will host a teleconference at 8:00 a.m....
Read More →FDA Approves Novartis Cosentyx for Adolescents with Hidradenitis Suppurativa
The FDA has approved Novartis’s Cosentyx (secukinumab) for pediatric patients aged 12 and older with moderate to severe hidradenitis suppurativa, making it the only IL-17A...
Read More →Study Shows Abbott's FreeStyle Libre Improves Glucose Management for Type 2 Diabetes Patients on Insulin
Results from the FreeDM2 randomized controlled trial demonstrate that Abbott’s FreeStyle Libre continuous glucose monitoring technology significantly improves glucose outcomes compared to traditional fingerstick testing...
Read More →Abbott and Real Madrid Team Up for Youth Soccer and Health Initiative Across the U.S.
Abbott and Real Madrid have launched the second edition of the Abbott Dream Team, a nationwide youth development program combining soccer training with health and...
Read More →Stryker Recovers from March Cyberattack, Confirms No Customer Data Compromised
Stryker Corporation experienced a cyberattack on March 11, 2026, affecting its Microsoft environment, but the company confirmed the incident was contained to its own internal...
Read More →Medtronic to Acquire Scientia Vascular for $550 Million to Bolster Neurovascular Portfolio
Medtronic has announced a definitive agreement to acquire Scientia Vascular, a Salt Lake City-based medical device company, for $550 million plus undisclosed earn-out and milestone...
Read More →Sanofi Board Proposes Orange Group CEO Christel Heydemann as Independent Director
Sanofi’s Board of Directors has proposed appointing Christel Heydemann as an independent director at the Annual General Meeting scheduled for April 29, 2026. The board...
Read More →Sanofi Files Amendment to French Annual Financial Report
Sanofi has filed an amendment to its Document d’Enregistrement Universel with France’s market authority, the Autorite des marches financiers. The submission includes additions to the...
Read More →Stryker Unveils 3D-Printed Knee Component and Robotic Surgery Advances at AAOS 2026
Stryker introduced several orthopaedic innovations at the AAOS 2026 Annual Meeting in New Orleans, headlined by Triathlon Gold, the company’s first commercially available femoral component...
Read More →Stryker Earns First-Ever Enterprise Gold Resiliency Badge for Supply Chain Excellence
The Healthcare Industry Resiliency Collaborative has awarded Stryker the Enterprise Gold Resiliency Badge, recognizing exceptional adaptability in healthcare supply chain performance. This is the first...
Read More →Sanofi's Rilzabrutinib Receives Orphan Drug Designation in Japan for IgG4-Related Disease
Japan’s Ministry of Health, Labour and Welfare has granted orphan drug designation to Sanofi’s rilzabrutinib for treating IgG4-related disease, marking the third global orphan drug...
Read More →EU Regulators Recommend Dupixent Approval for Young Children with Chronic Spontaneous Urticaria
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion recommending Dupixent (dupilumab) for treating chronic spontaneous urticaria in...
Read More →Single-Dose Sleeping Sickness Treatment From Sanofi Receives Positive EU Regulatory Opinion
The European Medicines Agency’s Committee for Medicinal Products for Human Use has granted a positive opinion to acoziborole (Acoziborole Winthrop) as a single-dose oral treatment...
Read More →UnitedHealth Group Board Authorizes $2.21 Per Share Quarterly Dividend
The UnitedHealth Group board of directors has authorized a cash dividend of $2.21 per share, payable on March 17, 2026, to shareholders of record as...
Read More →FDA Approves Dupixent as First and Only Treatment for Allergic Fungal Rhinosinusitis
The FDA has granted priority review approval to Dupixent (dupilumab), developed by Sanofi and Regeneron, for treating adults and pediatric patients aged 6 and older...
Read More →Sanofi Files 2025 Annual Financial Report with U.S. and French Regulators
Sanofi has filed its Form 20-F with the U.S. Securities and Exchange Commission and its Document d’Enregistrement Universel containing its Annual Financial Report with the...
Read More →Sanofi and Teva Report Durable Efficacy for Duvakitug in Inflammatory Bowel Disease Maintenance Study
The RELIEVE UCCD long-term extension study has shown that duvakitug, a human monoclonal antibody targeting TL1A developed by Sanofi and Teva Pharmaceutical Industries, maintained robust...
Read More →Lancet Study Shows Sanofi's Beyfortus Provides RSV Protection Beyond First Season for Infants
A study published in The Lancet Infectious Diseases has found that Sanofi’s Beyfortus (nirsevimab) provides significant protection against RSV hospitalizations not only during the first...
Read More →Sanofi Appoints Former Merck KGaA CEO Belen Garijo as New Chief Executive
Sanofi’s Board of Directors has appointed Belen Garijo as the company’s new Chief Executive Officer, effective at the conclusion of the Annual General Meeting on...
Read More →Sanofi Completes Acquisition of Dynavax, Expanding Adult Vaccine Portfolio
Sanofi has completed its acquisition of Dynavax Technologies Corporation, adding the hepatitis B vaccine HEPLISAV-B and a pipeline of vaccine assets to its portfolio. The...
Read More →Sanofi's Rilzabrutinib Earns FDA Breakthrough Therapy Designation for Rare Blood Disorder
The FDA has granted breakthrough therapy designation to Sanofi’s Wayrilz (rilzabrutinib) for warm autoimmune hemolytic anemia, making it the first and only investigational BTK inhibitor...
Read More →UnitedHealth Group Reports $447.6 Billion in 2025 Revenue, Issues 2026 Guidance
UnitedHealth Group reported full-year 2025 consolidated revenues of $447.6 billion, representing 12% year-over-year growth, alongside earnings from operations of $19.0 billion and a net margin...
Read More →UnitedHealth Group CEO Testifies Before Congress on Healthcare Affordability
UnitedHealth Group Chairman and CEO Stephen J. Hemsley testified before the House Energy and Commerce and Ways and Means Committees regarding healthcare affordability and accessibility...
Read More →UnitedHealthcare Launches Pilot to Accelerate Medicare Advantage Payments to Rural Hospitals
UnitedHealthcare has launched a Rural Payment Acceleration Pilot to assist independent rural hospitals experiencing financial strain. The six-month initiative reduces Medicare Advantage payment timelines by...
Read More →Independent Studies Find Medicare Advantage Costs Government 9% Less Than Traditional Medicare
Two independent actuarial studies conducted by Milliman and released by UnitedHealth Group found that Medicare Advantage costs the federal government 9% less than traditional Medicare....
Read More →No articles match your search.